A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Standard chemotherapy|DRUG: bevacizumab [Avastin]|DRUG: trastuzumab [Herceptin]
Sponsor: Hoffmann-La Roche